Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
Active, not recruiting · Phase 2 · NCT05502315
Conditions: Castration-resistant Prostate Cancer, Metastatic Cancer
At a glance
- Research payments reported, 2025
- $122,635
- U.S. investigators named
- 4
- Sites paid
- 4
- Planned or actual enrollment
- 47
About the trial
- Sponsor
- Rana McKay, MD (with Exelixis, Bristol-Myers Squibb)
- Tested
- Cabozantinib (drug), Nivolumab (drug)
- Dates
- Started 2023-02-02; completion 2027-11-12
- Results posted
- Not yet
This is a multicenter, single-arm, two-stage open-label phase 2 study of the combination of cabozantinib + nivolumab in subjects with advanced castration-resistant prostate cancer (CRPC).
From ClinicalTrials.gov, last updated 2026-11-02. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $122,635 in research payments for this study in 2025 (4 payments).
Products named: Opdivo
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Rana R. Mckay, MD Hematology & Oncology · San Diego, CA
- Akash Patnaik Hematology & Oncology · Chicago, IL
- Qian Qin, M.D. Medical Oncology · Dallas, TX
- Christos Kyriakopoulos, M.D. Hematology & Oncology · Verona, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Texas Southwestern $49,514
- Board of Regents of the University of Wisconsin Systems $37,633
- University of California San Diego $23,545
- The University of Chicago Kovler Diabetes Center $11,943
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.